Lifesci Capital Reiterates Outperform Rating for Perspective Therapeutics (NYSEAMERICAN:CATX)

Lifesci Capital reissued their outperform rating on shares of Perspective Therapeutics (NYSEAMERICAN:CATX) in a report released on Monday, Zacks.com reports. Lifesci Capital also issued estimates for Perspective Therapeutics’ FY2024 earnings at ($0.12) EPS and FY2025 earnings at ($0.14) EPS.

Several other research firms also recently issued reports on CATX. Oppenheimer restated an outperform rating and set a $1.50 target price (up previously from $1.20) on shares of Perspective Therapeutics in a research report on Monday, April 1st. B. Riley raised their target price on Perspective Therapeutics from $1.20 to $1.70 and gave the stock a buy rating in a research note on Tuesday, April 9th.

Perspective Therapeutics Trading Down 4.3 %

Shares of NYSEAMERICAN:CATX opened at 1.76 on Monday. The stock has a market cap of $1.03 billion, a price-to-earnings ratio of -17.60 and a beta of 1.43. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.07 and a quick ratio of 1.07. Perspective Therapeutics has a twelve month low of 0.21 and a twelve month high of 1.90.

Insider Activity at Perspective Therapeutics

In other Perspective Therapeutics news, major shareholder Lantheus Alpha Therapy, Llc acquired 60,431,039 shares of the business’s stock in a transaction dated Wednesday, March 6th. The stock was bought at an average price of 0.95 per share, with a total value of 57,409,487.05. Following the purchase, the insider now owns 116,773,394 shares of the company’s stock, valued at 110,934,724.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 3.52% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Perspective Therapeutics

Several institutional investors have recently bought and sold shares of the stock. ZWJ Investment Counsel Inc. bought a new position in Perspective Therapeutics during the 1st quarter valued at approximately $26,000. Bleakley Financial Group LLC purchased a new position in shares of Perspective Therapeutics during the first quarter valued at approximately $40,000. Simplicity Wealth LLC bought a new position in shares of Perspective Therapeutics during the first quarter valued at approximately $40,000. Taylor & Morgan Wealth Management LLC raised its holdings in Perspective Therapeutics by 8.7% in the 4th quarter. Taylor & Morgan Wealth Management LLC now owns 625,000 shares of the company’s stock worth $251,000 after purchasing an additional 50,000 shares in the last quarter. Finally, RIA Advisory Group LLC lifted its holdings in Perspective Therapeutics by 1,313.4% in the first quarter. RIA Advisory Group LLC now owns 106,853 shares of the company’s stock worth $127,000 after buying an additional 99,293 shares during the period. 54.66% of the stock is currently owned by hedge funds and other institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.